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Objective: In 1996, we introduced the free tracheal autograft technique for repair of
congenital tracheal stenosis from complete tracheal rings in infants and children.
Sources of possible concern with this procedure include the potential for autograft
ischemia, patch dehiscence, and recurrent stenosis. Vascular endothelial growth fac-
tor is a potent angiogenic inducer (particularly in the setting of ischemia, hypoxia,
or both) and is postulated to promote tissue healing. The purpose of this study was
to test the hypothesis that pretreatment of tracheal autografts with topical vascular
endothelial growth factor would enhance tracheal healing.
Methods: In a rabbit model of tracheal reconstruction (n = 32), an elliptically
shaped portion of the anterior tracheal wall was excised. The excised portion of tra-
chea was one third of the tracheal circumference and 2 cm in length (6 tracheal
rings). This portion of trachea (the autograft) was soaked in either vascular endothe-
lial growth factor (5 µg/mL, n = 16) or normal saline solution (n = 16) for 15 min-
utes before being reimplanted in the resultant tracheal opening. Animals were killed
and autografts were examined at 2 weeks, 1 month, and 2 months postoperatively
for gross and microscopic characteristics.
Results: By 2 weeks, and progressing through 1 and 2 months, autografts treated
with vascular endothelial growth factor, as compared with control autografts, had
reduced luminal stenosis, submucosal fibrosis, and inflammatory infiltrate (P <
.05). The autografts tended to become malaligned in control animals, whereas the
tracheal architecture was preserved in rabbits treated with vascular endothelial
growth factor. Microvascular vessel density was significantly greater in all vascular
endothelial growth factor groups (P < .05) at all time intervals.
Conclusions: Topical treatment of free tracheal autografts with vascular endothe-
lial growth factor in a rabbit tracheal reconstruction model enhanced healing, as
evidenced by accelerated autograft revascularization, reduced submucosal fibro-
sis and inflammation, and preservation of the normal tracheal architecture.
Topical vascular endothelial growth factor may improve future results of tracheal
reconstruction.
Tracheal stenosis caused by congenital complete cartilaginous tra-cheal rings often involves the entire length of the trachea, and theseinfants frequently have life-threatening respiratory distress. Manysurgical techniques have been developed to manage this complexanomaly. These include resection and end-to-end anastomosis,1,2pericardial patch tracheoplasty,3-5 rib cartilage tracheoplasty,6-8 slide
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tracheoplasty,9-11 and the free tracheal autograft.12,13 More
recently, cryopreserved tracheal allografts have been shown
to have encouraging results in salvage procedures after fail-
ure of one of the described primary techniques.14,15 Our best
clinical results have been obtained with the tracheal auto-
graft technique.
Vascular endothelial growth factor (VEGF) is a secreted
glycoprotein and a potent endothelial cell–derived angiogenic
factor that acts through 2 receptors, flk-1 and flt-1.16 VEGF is
particularly important in the setting of tissue ischemia.17
VEGF has been noted in tracheal granulation tissue in chil-
dren and in normoxic wound fluid.18,19 VEGF has been
implicated in enhanced wound healing, increased vascular
permeability, angiogenesis, and the stimulation of nitric oxide
release from vascular endothelial cells.20-23 We proposed this
study in rabbits to evaluate the revascularization and healing
process of the autograft and to examine the potential effect on
the autograft of topical VEGF. The excised autograft is com-
pletely devascularized before reimplantation for tracheal
reconstruction. It is therefore subjected to a period of hypox-
ia-ischemia that might contribute to imperfect healing, exces-
sive scarring, or both. In a rabbit model simulating repair of
congenital tracheal stenosis with a free tracheal autograft, we
set out to histologically define the healing process of the auto-
graft. Furthermore, an attempt was made to determine
whether pretreating tracheal autografts with topical VEGF
before reimplantation would enhance local angiogenesis and
thus improve tracheal healing.
Materials and Methods
Thirty-two New Zealand White rabbits (16 male and 16 female;
weight range, 1.8-3.3 kg; mean weight, 2.5 kg) underwent a tra-
cheal autograft procedure according to the study protocol. All ani-
mals received humane care in compliance with the “Guide for the
Care and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996.
Anesthetic induction was done by using intramuscular acepro-
mazine (1-2 mg/kg), followed by intramuscular ketamine and
xylazine (35-50 mg/kg and 5-10 mg/kg, respectively). The rabbits
then had their necks shaved, had an intravenous line placed, and
underwent pulse-oximetry monitoring. Rabbits at this point were
breathing spontaneously. After sterile preparing and draping, a
midline collar incision was made, with dissection of the muscular
planes down to the trachea. A horizontal tracheal incision was then
made, opening one third of the tracheal circumference 3 to 4 rings
below the vocal cords. A sterile endotracheal tube (3.5F) was
introduced without a cuff and in a retrograde manner through the
tracheotomy, through the vocal cords, and out of the mouth. The
tube was connected to the ventilator, and anesthesia was continued
with inhaled isoflurane (1%-2%). This technique of retrograde
intubation was developed after the third case, when repetitive
attempts to intubate in a standard antegrade fashion were judged to
be unnecessarily traumatic to the vocal cords and larynx, as well as
excessively time consuming. The endotracheal tube tip was posi-
tioned just above the carina and below the area where the proce-
dure was being performed. The tracheal incision was then carried
inferiorly to complete the excision of an elliptical anterior auto-
graft (Figure 1). The autograft consisted of one third of the tracheal
circumference and included 6 cartilage rings (2 cm in length). The
endotracheal tube tip remained well beyond the most distal part of
the defect thus created, so that mechanical ventilation of the ani-
mal proceeded without difficulty. The excised autograft was then
immersed in either a solution containing human recombinant
VEGF (5 µg/mL; n = 16; R&D Systems, Minneapolis, Minn) or
normal saline solution (n = 16) for 15 minutes. Randomization was
performed by using VEGF on every other animal. During this time,
Figure 1. Autograft technique. An elliptical tracheal autograft is harvested from the trachea (left panel). The auto-
graft is then soaked in a Petri dish for 15 minutes with either saline solution or the VEGF solution (middle panel).
The autograft is then secured in place in the tracheal opening with interrupted PDS (polydiaxanone) sutures (right
panel).
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interrupted 6-0 PDS (polydioxanone) sutures (Ethicon Inc,
Somerville, NJ) were placed circumferentially around the defect
(Figure 1). The sutures were then passed through the edges of the
circumference of the autograft, the autograft was lowered into the
defect, and all the sutures were tied and cut. Use of intermittent
squirts of either normal saline or VEGF solution, according to the
treatment protocol, kept the autograft from desiccating during this
phase. During continued ventilation, the surgical site was
immersed with saline solution to assess for air leaks, and addition-
al interrupted PDS sutures were added as necessary. The wound
was then closed with 2 layers of continuous 4-0 Vicryl sutures
(Ethicon, Inc) for the muscular layer and continuous 4-0 Vicryl
sutures in the subcuticular layer. The procedures were done under
enrofloxacine prophylaxis (5 mg/kg) administered intravenously
before the skin incision and administered intramuscularly every 12
hours postoperatively for 72 hours. Postoperative pain manage-
ment consisted of subcutaneous buprenorphine (0.05 mg/kg) every
12 hours as required.
Rabbits were killed with intravenous pentobarbital (150 mg/kg)
in 3 groups of 10 animals each at 2 weeks, 1 month, and 2 months,
respectively. In each group, 5 animals were treated with VEGF, and
5 were control animals. The tracheas were excised from larynx to
carina and divided along the posterior wall longitudinally to keep the
autograft patch intact. At the aforementioned intervals, healing char-
acteristics were compared between the 2 groups to determine the
effect of topical VEGF on a devascularized free tracheal autograft.
The autografts were placed in 10% buffered formalin overnight. The
specimens were embedded in paraffin, and 5-µm sections were
placed on glass slides. Each slide was stained with hematoxylin-
phloxine-saffarin to highlight fibrous tissue. The pathologist (S.C.)
grading the specimens was blinded to whether the specimens were
treated or untreated. In 4 rabbits in each group, macroscopic assess-
ment was performed for luminal stenosis and tracheal wall configu-
ration, and microscopic scoring was performed by evaluating the
degree of submucosal fibrosis and inflammation. In one rabbit in
each group, microvascular density (MVD) was assessed by counting
the number of endothelial cell–lined channels in 5 separate high-
power fields. Immunohistochemical localization of VEGF was per-
formed on fixed tissue sections by a standard ABC protocol and anti-
body to VEGF (R&D Systems). The slides were counterstained with
hematoxylin, and the intensity of VEGF staining was graded in a
blinded fashion.
We compared the difference in the degree of luminal stenosis of
the tracheal wall between control and VEGF-treated rabbits at 2
weeks, 1 month, and 2 months after a tracheal autograft by using
an exact Wilcoxon test.24 Statistical comparisons between control
and treated rabbits were done separately at each time period. We
conducted similar analyses for differences in the following out-
comes: autograft alignment, submucosal fibrosis, and inflammato-
ry infiltrate. To compare the difference in MVD between control
and VEGF-treated rabbits, we used a Wilcoxon rank-sum test.25
We used SAS version 7 software for the calculation of exact
Wilcoxon P values (SAS Institute, Cary, NC).
Results
The operative procedure was considered successful in 30
(93.8%) of 32 animals, and 30 animals survived until the
end of the experimental period. In the early phase of the
experiment, there were 2 deaths (1 in the control group and
1 in the treatment group) on the first postoperative day as a
result of acute respiratory distress. Autopsy examination
revealed macroscopic evidence of tracheal stenosis at the
site of repair associated with edema of the vocal cords and
larynx. These deaths were attributed to the learning curve
involved with the antegrade intubation technique and with
the autograft procedure itself.
Tables 1 to 5 summarize the gross and microscopic
results comparing control rabbits with VEGF-treated rabbits
at 2 weeks, 1 month, and 2 months postoperatively. Gross
evaluation of the autograft specimens in the 2 groups
revealed essentially no luminal stenosis (Table 1) or auto-
graft malalignment (Table 2) in the VEGF-treated group at
all time points. In contrast, the control groups had progres-
sive luminal stenosis (Table 1) and autograft malalignment
(Table 2). Microscopic evaluation of the VEGF-treated ani-
mals showed a mild degree of submucosal fibrosis at 1 and
2 months (Table 3), although it did not alter the luminal
integrity of the autograft (Figure 2). These findings were in
striking contrast to those in the control group, in which there
was progressive submucosal fibrosis that was severe by 2
months (Table 3). At 2 months, the control animals demon-
strated significant impingement of the lumen caused by a
marked fibroblastic proliferation (Figure 2, C, arrow).
An unexpected histologic finding was a difference in the
inflammatory response between the 2 groups. In the control
TABLE 1. Difference in luminal stenosis of the tracheal orifice between control (n = 12) and VEGF-treated (n = 12) rabbits at
2 weeks, 1 month, and 2 months after a tracheal autograft procedure
2 wk 1 mo 2 mo
Luminal stenosis Control VEGF* Control VEGF* Control VEGF*
No stenosis 0 4 0 4 0 3
<10% stenosis 3 0 1 0 0 1
10%-25% stenosis 1 0 3 0 0 0
26%-50% stenosis 0 0 0 0 3 0
51%-100% stenosis 0 0 0 0 1 0
*All P < .05 (exact Wilcoxon P value = .0286).
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group, all animals had an early and persistent inflammato-
ry infiltrate located adjacent to the site of repair (Table 4).
The inflammatory cell population in both groups was com-
posed of predominantly lymphocytes and occasionally
eosinophils. All animals in the VEGF-treated group demon-
strated a similar inflammatory response at 2 weeks; how-
ever, the inflammatory process appeared to resolve, and by
2 months, no aggregates of lymphocytes were observed in
any of the treated autograft specimens (Table 4). These data
suggest that VEGF may play a suppressive role in immune
modulation, and this may be one mechanism responsible
for its ability to enhance wound healing and limit fibrosis.
MVD was assessed by counting the number of endothe-
lial cell–lined channels in 5 high-power fields in one auto-
graft in each group to determine whether VEGF, a potent
inducer of angiogenesis, improved the revascularization of
the autografts. By 2 weeks, both groups showed evidence
of revascularization of the autograft (Table 5). However,
the VEGF-treated group had more than a 2-fold increase in
MVD when compared with the control group (8.8 vs 21.2;
P = .012, Wilcoxon rank-sum test). The increase in neo-
vascularization of the autografts persisted at 1 and 2
months in the VEGF-treated groups (Table 5 and Figure 3,
A vs B). The vessels tended to be arranged in clusters with-
out significant red blood cell extravasation, suggesting that
vascular leakage was not a complicating factor.
Because the exposure of the autograft to VEGF was
relatively short, it was important to determine whether
TABLE 3. Difference in submucosal fibrosis of the tracheal wall between control (n = 12) and VEGF-treated (n = 12) rabbits
at 2 weeks, 1 month, and 2 months after a tracheal autograft procedure
2 wk 1 mo 2 mo
Submucosal fibrosis Control VEGF* Control VEGF* Control VEGF*
None 0 4 0 1 0 0
Focal 1 0 0 1 0 2
Mild 2 0 0 2 0 2
Moderate 1 0 2 0 1 0
Severe 0 0 2 0 3 0
*All P < .05 (exact Wilcoxon P value = .0286).
TABLE 2. Difference in autograft alignment of the tracheal wall between control (n = 12) and VEGF-treated (n = 12) rabbits
at 2 weeks, 1 month, and 2 months after a tracheal autograft procedure
2 wk 1 mo 2 mo
Autograft alignment Control VEGF* Control VEGF* Control VEGF*
No malalignment 0 4 0 3 0 3
Mild malalignment 0 0 0 1 0 1
Mild-moderate malalignment 3 0 0 0 0 0
Moderate malalignment 1 0 2 0 2 0
Severe malaligment 0 0 2 0 2 0
*All P < .05 (exact Wilcoxon P value = .0286).
TABLE 4. Difference in inflammatory infiltrate of the tracheal wall between control (n = 12) and VEGF-treated (n = 12) 
rabbits at 2 weeks, 1 month, and 2 months after a tracheal autograft procedure
2 wk 1 mo 2 mo
Inflammatory infiltrate Control VEGF* Control VEGF* Control VEGF*
None 0 0 0 2 0 4
Focal 0 2 0 1 0 0
Mild 0 2 0 1 0 0
Moderate 4 0 3 0 2 0
Severe 0 0 1 0 2 0
*All P < .05 (exact Wilcoxon P value = .0286).
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TABLE 5. Microvascular density
2 wk 1 mo 2 mo
High-power field No. Control VEGF Control VEGF Control VEGF
1 9 21 14 36 17 41
2 11 26 18 42 14 46
3 6 19 13 31 12 44
4 16 22 10 33 19 38
5 6 18 7 43 25 40
Mean 8.2 21.2 14.4 37.0 17.4 41.8
MVD was assessed in each autograft by counting the number of endothelial cell–lined channels (vessel density) in 5 separate high-power fields. At 2
weeks, the difference in MVD between control (mean = 8.2) and VEGF-treated (mean = 21.2) rabbits was statistically significant (P = .012, Wilcoxon rank-
sum test). At 1 month, the difference in MVD between control (mean = 14.4) and VEGF-treated (mean = 37.0) rabbits was statistically significant (P < .01,
Wilcoxon rank-sum test). At 2 months, the difference in MVD between control (mean = 17.4) and VEGF-treated (mean = 41.8) rabbits was statistically sig-
nificant (P < .01, Wilcoxon rank-sum test).
Figure 2. Photomicrographs of tracheal autografts at 2 months postoperatively at low and high power (hema-
toxylin-phloxine-saffarin stain): A and C, untreated; B and D, VEGF treated. A versus B: Note the malalignment of
the tracheal cartilage in the untreated graft (A) caused by excessive fibrosis causing distortion of the tracheal
alignment at the autograft tracheal junction (arrow). C versus D: C, High power showing distortion (arrow) at anas-
tomosis caused by excessive submucosal fibrosis (pink-staining fibroblasts adjacent to arrow). D, Medium power
of treated graft shows normal-appearing submucosa. L, Lumen.
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this elevated MVD was due to higher tissue localization
of VEGF. Immunohistochemical studies confirmed
intense immunostaining for VEGF in the submucosal
region in the treated group, whereas only minimal VEGF
expression was observed in the control group (compare
Figure 3, C, with Figure 3, D). The tracheal epithelium in
the treated group was uniform, with intact cilia and an
occasional goblet-appearing cell. These data suggest that
a brief exposure to topical VEGF is sufficient to increase
tissue revascularization, and VEGF continues to be secret-
ed by the numerous endothelial cells in the submucosa.
We postulate that this is due to a positive feedback loop.
It localizes in the interstitial matrix and spares the tra-
cheal epithelial cells. Moreover, 2 potential adverse bio-
logic actions of VEGF, increased vascular permeability
and pathologic endothelial cell proliferation, were not
observed in this experimental model, suggesting that top-
ical VEGF has minimal unfavorable side effects.
Discussion
Tracheal stenosis from congenital complete tracheal rings is
a rare anomaly characterized by an absence of the membra-
nous portion of the trachea. The tracheal stenosis may be
segmental, funnel-like, or in the form of generalized tra-
cheal hypoplasia, as classified by Cantrell and Guild.26
Severe respiratory distress is often apparent early in the
neonatal period. Various reconstruction techniques and
materials for repair have been developed in the treatment of
congenital tracheal stenosis. The severity of the tracheal
anatomy, especially the length of the stenosed portion, dic-
tates the choice of repair to a large degree. Primary recon-
struction with end-to-end anastomosis may relieve short
Figure 3. High-power photomicrographs of tracheal autografts at 2 months postoperatively: A and C, untreated; B
and D, VEGF treated; A and B, hematoxylin-phloxine-saffarin stain, C and D, immunohistochemical stain with anti-
body to VEGF. A versus B: High power demonstrates increased MVD (at least a 3-fold increase) in B compared with
that in A. The pink band underlying the epithelium in A is excessive submucosal fibrosis, which is not present in
B. In B there is a more evenly deposited matrix, which is evidence of more structural integrity. C versus D: There
is a striking increase in VEGF localization (denoted by brown color) in the submucosa of the treated autografts (C)
compared with that in the untreated autograft (D). Note the surface epithelium is spared of VEGF. VEGF is local-
ized to the submucosa, which is the site of healing and revascularization.
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segmental stenosis,1,2 but longer segments of stenosis
require more creative techniques. Idriss and colleagues3 first
reported pericardial patch tracheoplasty with cardiopul-
monary bypass in 1984. Advantages of pericardium include
easy availability, absence of rejection of autologous tissue, a
low metabolic rate requiring minimal blood supply, and
eventual re-epithelialization.27 Disadvantages include the
absence of structural rigidity, leading to patch tracheomala-
cia and tracheal narrowing, and frequent excessive granula-
tion tissue. One center reported a 47% mortality with this
procedure because of the above-mentioned complications.28
Various other autologous graft materials have been used in
conjunction with or as replacements for pericardium, such
as costal cartilage.6-8 Tsang and coworkers9 introduced the
slide tracheoplasty technique. This involves a transverse
division of the trachea at the midpoint of the stenosis, spat-
ulating the proximal and distal ends, followed by direct
anastomosis of the 2 tracheal segments. Grillo10 and Lang
and associates11 have reported good results with this tech-
nique. Nakanishi and colleagues29 experimented with tra-
cheal autografts in dogs. They found that autografts longer
than 4.0 cm (8-10 rings) showed stenosis, dissolution, or
both, in the middle part of the graft. Our group recently pub-
lished its results with free tracheal autografts with and with-
out pericardium.12,13 Advantages of a free tracheal autograft
include use of autologous tissue already lined with respira-
tory epithelium and inherent structural integrity. There is
potential for growth, the operation is reproducible and tech-
nically easy, and there is minimal tension on the suture
lines. However, in all cases we have been concerned about
the potential for autograft ischemia, patch dehiscence, and
recurrent stenosis. Despite a survival in our series of over
90%, a few patients have had prolonged hospitalization as a
result of recurrent granulation tissue and stenosis from exu-
berant scar formation.
VEGF, also known as vascular permeability factor, is a
soluble dimeric protein existing in 4 isoforms that is secret-
ed by numerous cell types. It is an endothelial cell–specific
mitogen and an angiogenic inducer by in vitro and in vivo
assays, promoting its effect through the specific receptors
flk-1 and flt-1.16,17,19,20 It also induces endothelium-depen-
dent vasodilatory responses through stimulation of the
release of nitric oxide from the endothelial cell19 and is
implicated in wound healing through its angiogenic activi-
ties.20 VEGF secretion is upregulated by hypoxic stress,
ischemia, and anemia.17,20
Pokharel and colleagues18 recently demonstrated aug-
mented expression of VEGF protein and mRNA in tracheal
granulation tissue specimens after prolonged intubation in
children. Increased VEGF levels were found in those epithe-
lial cells and macrophages that migrated to infiltrate the
granulation tissue. They speculated that enhanced VEGF
expression may play a pivotal role in granulation tissue
development. Albes and colleagues30 investigated whether
another angiogenic inducer, basic fibroblast growth factor
(bFGF), can enhance the blood supply of an ischemic auto-
graft that was placed in a subcutaneous pouch. They con-
cluded that application of bFGF increased revascularization
and resulted in improved epithelial preservation. Corral and
associates31 demonstrated, in a rabbit skin ulcer model, that
topical VEGF was more effective than bFGF during
ischemic wound healing.
We hypothesized that through enhanced local angiogen-
esis and microvascular vasodilation, devascularized free tra-
cheal autografts treated with topical VEGF would revascu-
larize and heal better than control grafts in a rabbit model of
tracheal reconstruction. At 2 weeks, 1 month, and 2 months
after reimplantation, gross and histologic examination of the
treated grafts demonstrated an enhanced healing process.
Fibrous tissue formation leading to potential stricture and
localized airway obstruction was significantly less in the
VEGF-treated rabbit autografts. Histologically, MVD was
increased and inflammation was decreased in the VEGF
group. We postulate that a more abundant blood supply was
one mechanism underlying the improved healing. This
enhanced healing resulted in less protrusion of the graft into
the airway lumen. Of note, at 2 months postoperatively,
there was stabilization of the MVD back to normal ranges.
This represents an important finding in that a relative quies-
cence in the vasculature was noted over the relatively short
time period of the study.
There are some interesting findings in our experiment for
which we do not necessarily have an explanation. We noted
an increase in VEGF localization (Figure 3), even at 2
months postoperatively. We speculate that this is due to
some form of positive feedback loop but have no data to
support this. We have not looked at mRNA expression in the
autografts or at immune mechanisms for VEGF action.
Topical VEGF treatment of free tracheal autografts in a
rabbit tracheal reconstruction model accelerated revascu-
larization, increased MVD, reduced inflammation, sup-
pressed submucosal fibrosis, and preserved architectural
integrity. It is extrapolated from these observations that
enhanced graft healing promoted by topical VEGF admin-
istration results in an improved airway that could be an
important adjunct to the surgical repair of congenital tra-
cheal stenosis in infants and children. Postoperative intu-
bation times could be reduced, as could the number of
treatments with a rigid bronchoscope required for granu-
lation tissue debridement. Potentially, topical treatment
with VEGF represents a single pulse of a healing boost in
the setting of tissue injury at the precise time when
hypoxia-ischemia and resultant necrosis can be most men-
acing. The optimal concentration and exposure time to
topical VEGF still need to be determined in an experi-
mental setting. We speculate that topical VEGF may be an
General Thoracic Surgery Dodge-Khatami et al
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important adjunctive therapy to improve clinical results of
surgical repair of congenital tracheal stenosis.
We thank William Checkley, ScM, Biostatistics, for statistical
analysis of the study data.
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